These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 23098110)
1. Targeted treatment for melanoma. Monga M; Abraham J Expert Rev Anticancer Ther; 2012 Sep; 12(9):1113-5. PubMed ID: 23098110 [No Abstract] [Full Text] [Related]
2. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma. Long G Clin Adv Hematol Oncol; 2018 Jan; 16(1):25-27. PubMed ID: 29741501 [No Abstract] [Full Text] [Related]
3. Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond. Sullivan RJ; Atkins MB Expert Opin Investig Drugs; 2010 Oct; 19(10):1205-16. PubMed ID: 20687784 [TBL] [Abstract][Full Text] [Related]
4. Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy? Passeron T; Lacour JP; Allegra M; Ségalen C; Deville A; Thyss A; Giacchero D; Ortonne JP; Bertolotto C; Ballotti R; Bahadoran P Exp Dermatol; 2011 Dec; 20(12):1030-2. PubMed ID: 22092579 [TBL] [Abstract][Full Text] [Related]
6. New therapeutic targets in melanoma. Martí RM; Sorolla A; Yeramian A Actas Dermosifiliogr; 2012 Sep; 103(7):579-90. PubMed ID: 22261672 [TBL] [Abstract][Full Text] [Related]
7. [ASCO highlights in the treatment of metastatic melanoma]. Hertlein A Med Monatsschr Pharm; 2014 May; 37(5):183-4. PubMed ID: 24908933 [No Abstract] [Full Text] [Related]
8. Genetic alterations and personalized medicine in melanoma: progress and future prospects. Griewank KG; Scolyer RA; Thompson JF; Flaherty KT; Schadendorf D; Murali R J Natl Cancer Inst; 2014 Feb; 106(2):djt435. PubMed ID: 24511108 [TBL] [Abstract][Full Text] [Related]
9. Oncogenetics of melanoma: basis for molecular diagnostics and therapy. Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632 [TBL] [Abstract][Full Text] [Related]
10. BRAF inhibitors and melanoma. Flaherty KT Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295 [TBL] [Abstract][Full Text] [Related]
12. Major therapeutic developments and current challenges in advanced melanoma. Sullivan RJ; Flaherty KT Br J Dermatol; 2014 Jan; 170(1):36-44. PubMed ID: 24443912 [TBL] [Abstract][Full Text] [Related]
13. Personalized-medicine trials on the rise. Benowitz S J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496 [No Abstract] [Full Text] [Related]
14. BRAF, a target in melanoma: implications for solid tumor drug development. Flaherty KT; McArthur G Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085 [TBL] [Abstract][Full Text] [Related]
15. Is it good or bad to find a BRAF mutation? Flaherty KT J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552 [No Abstract] [Full Text] [Related]
16. On or off target: mutations, models, and predictions. Garraway LA; Hahn WC Sci Transl Med; 2010 Jun; 2(35):35ps28. PubMed ID: 20538617 [TBL] [Abstract][Full Text] [Related]
17. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Gollob JA; Wilhelm S; Carter C; Kelley SL Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795 [TBL] [Abstract][Full Text] [Related]
18. Targeted therapy for thyroid cancer: striking the survival signaling. Vitale M J Clin Endocrinol Metab; 2011 Apr; 96(4):936-8. PubMed ID: 21474689 [No Abstract] [Full Text] [Related]
19. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559 [TBL] [Abstract][Full Text] [Related]
20. [Clinical studies in oncology--a challenge for clinical and academic pathology]. Röcken C Dtsch Med Wochenschr; 2013 May; 138(20):1073-6. PubMed ID: 23670265 [No Abstract] [Full Text] [Related] [Next] [New Search]